Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: Recent insights

Jason S. Starr, Mohamad Bassam Sonbol, Timothy J. Hobday, Akash Sharma, Ayse Tuba Kendi, Thorvardur R. Halfdanarson

Research output: Contribution to journalReview articlepeer-review

Abstract

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.

Original languageEnglish (US)
Pages (from-to)3545-3555
Number of pages11
JournalOncoTargets and Therapy
Volume13
DOIs
StatePublished - 2020

Keywords

  • PRRT
  • PanNET
  • Pancreatic neuroendocrine tumor
  • Peptide receptor radionuclide therapy
  • Theranostics

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: Recent insights'. Together they form a unique fingerprint.

Cite this